Risk factors for increasing pp65 antigenemia among 119 recipients of allogeneic HSCT
| . | OR . | ↑ Ag > 2× baseline . | OR . | ↑ Ag > 5× baseline . | ||
|---|---|---|---|---|---|---|
| 95% CI . | P . | 95% CI . | P . | |||
| Univariate analysis | ||||||
| Donor CMV serostatus | ||||||
| Positive | 1.0* | 1.0* | ||||
| Negative | 2.5 | 1.2 -5.4 | .02 | 2.9 | 1.3 -6.8 | .01 |
| Donor type | ||||||
| Matched sibling | 1.0* | 1.0* | ||||
| Mismatched related | 0.6 | 0.2 -2.6 | .52 | 0.3 | 0.03 -2.3 | .23 |
| Unrelated | 3.3 | 1.5 -7.5 | .004 | 2.7 | 1.1 -6.4 | .03 |
| Conditioning | ||||||
| Non–TBI-containing | 1.0* | 1.0* | ||||
| TBI-containing | 3.4 | 1.4 -8.0 | .006 | 4.1 | 1.5 -11.8 | .008 |
| Acute GVHD† | ||||||
| Grades 0-1 | 1.0* | 1.0* | ||||
| Grades 2-4 | 3.9 | 1.3-11.1 | .01 | 14.3 | 1.8 -110.7 | .01 |
| Grades 3-4 | 1.6 | 0.7 -3.6 | .25 | 1.7 | 0.7 -4.1 | .22 |
| Steroid use at 1st Ag + ve | ||||||
| None | 1.0* | 1.0* | ||||
| <1 mg/kg | 4.1 | 0.9-17.4 | .06 | 4.3 | 0.4 -51.3 | .25 |
| 12 mg/kg | 4.3 | 1.2-15.3 | .03 | 14.3 | 1.7 -120.2 | .01 |
| ≥2 mg/kg | 10.5 | 3.1-35.8 | .0002 | 28.6 | 3.6 -229.7 | .002 |
| Multivariate analysis‡ | ||||||
| Conditioning | ||||||
| Non–TBI-containing | 1.0* | |||||
| TBI-containing | 2.6 | 1.0 -6.8 | .04 | |||
| Steroid use at 1st Ag + ve | ||||||
| None | 1.0* | 1.0* | ||||
| <1 mg/kg | 5.0 | 1.0-24.5 | .05 | 4.3 | 0.4 -51.3 | .25 |
| 1-2 mg/kg | 4.0 | 1.0-16.8 | .06 | 14.3 | 1.7 -120.2 | .01 |
| ≥2 mg/kg | 10.1 | 2.6-40.2 | .001 | 28.6 | 3.6 -229.7 | .002 |
| . | OR . | ↑ Ag > 2× baseline . | OR . | ↑ Ag > 5× baseline . | ||
|---|---|---|---|---|---|---|
| 95% CI . | P . | 95% CI . | P . | |||
| Univariate analysis | ||||||
| Donor CMV serostatus | ||||||
| Positive | 1.0* | 1.0* | ||||
| Negative | 2.5 | 1.2 -5.4 | .02 | 2.9 | 1.3 -6.8 | .01 |
| Donor type | ||||||
| Matched sibling | 1.0* | 1.0* | ||||
| Mismatched related | 0.6 | 0.2 -2.6 | .52 | 0.3 | 0.03 -2.3 | .23 |
| Unrelated | 3.3 | 1.5 -7.5 | .004 | 2.7 | 1.1 -6.4 | .03 |
| Conditioning | ||||||
| Non–TBI-containing | 1.0* | 1.0* | ||||
| TBI-containing | 3.4 | 1.4 -8.0 | .006 | 4.1 | 1.5 -11.8 | .008 |
| Acute GVHD† | ||||||
| Grades 0-1 | 1.0* | 1.0* | ||||
| Grades 2-4 | 3.9 | 1.3-11.1 | .01 | 14.3 | 1.8 -110.7 | .01 |
| Grades 3-4 | 1.6 | 0.7 -3.6 | .25 | 1.7 | 0.7 -4.1 | .22 |
| Steroid use at 1st Ag + ve | ||||||
| None | 1.0* | 1.0* | ||||
| <1 mg/kg | 4.1 | 0.9-17.4 | .06 | 4.3 | 0.4 -51.3 | .25 |
| 12 mg/kg | 4.3 | 1.2-15.3 | .03 | 14.3 | 1.7 -120.2 | .01 |
| ≥2 mg/kg | 10.5 | 3.1-35.8 | .0002 | 28.6 | 3.6 -229.7 | .002 |
| Multivariate analysis‡ | ||||||
| Conditioning | ||||||
| Non–TBI-containing | 1.0* | |||||
| TBI-containing | 2.6 | 1.0 -6.8 | .04 | |||
| Steroid use at 1st Ag + ve | ||||||
| None | 1.0* | 1.0* | ||||
| <1 mg/kg | 5.0 | 1.0-24.5 | .05 | 4.3 | 0.4 -51.3 | .25 |
| 1-2 mg/kg | 4.0 | 1.0-16.8 | .06 | 14.3 | 1.7 -120.2 | .01 |
| ≥2 mg/kg | 10.1 | 2.6-40.2 | .001 | 28.6 | 3.6 -229.7 | .002 |
Variables found not significant in univariate analysis were age, gender, underlying disease, disease risk, and GVHD prophylaxis.
Reference category.
If GVHD occurred after a rise in antigenemia level, this was regarded as grades 0-1 in the regression model.
For > 2× baseline, the likelihood ratio test for adding donor type to the model above yielded P = .16; for donor CMV serostatus, P = .25; for grades 2-4 GVHD,P = .73. For > 5× baseline, the likelihood ratio test for adding TBI-containing conditioning to the model above yieldedP = .09; for donor type, P = .13; for donor CMV serostatus, P = .09; for grades 2-4 GVHD,P = .23.